Participants 58 120 5
patients with hepatitis C virus-related chronic liver disease.
Participants 285 351 6
101 patients with hepatitis C virus-related chronic liver disease.
Participants 360 479 6
Forty-nine patients were assigned to receive UDCA (450 mg/day) over a period of 6 months and 52 to receive no treatment
